Drug combination before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer) and palbociclib (a targeted therapy that stops cancer cells from growing)—given before surgery for esophageal cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell cancer of the esophagus, confirmed by a biopsy.
- The tumor should be in the chest area and your doctor believes it can be completely removed with surgery.
- You must be between 18 and 75 years old and in generally good health (able to do light work or be fully active).
- Your major organs (heart, lungs, liver, kidneys) and blood counts should be working normally.
- You must be willing to have surgery and to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (ivonescimab) plus chemotherapy given before surgery for esophageal cancer. The goal is to see if it can shrink the tumor and improve outcomes compared to surgery alone.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
Hear when a new Esophageal Squamour Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.